- Home
- HOWL vs VIGL Comparison
HOWL vs VIGL Comparison
Compare HOWL & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- VIGL
- Stock Information
- Founded
- HOWL 2017
- VIGL 2020
- Country
- HOWL United States
- VIGL United States
- Employees
- HOWL N/A
- VIGL N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- VIGL Health Care
- Exchange
- HOWL Nasdaq
- VIGL Nasdaq
- Market Cap
- HOWL 53.4M
- VIGL 134.9M
- IPO Year
- HOWL 2021
- VIGL 2022
- Fundamental
- Price
- HOWL $1.10
- VIGL $7.96
- Analyst Decision
- HOWL Strong Buy
- VIGL Buy
- Analyst Count
- HOWL 3
- VIGL 7
- Target Price
- HOWL $8.33
- VIGL $8.00
- AVG Volume (30 Days)
- HOWL 648.5K
- VIGL 1.5M
- Earning Date
- HOWL 08-07-2025
- VIGL 08-12-2025
- Dividend Yield
- HOWL N/A
- VIGL N/A
- EPS Growth
- HOWL N/A
- VIGL N/A
- EPS
- HOWL N/A
- VIGL N/A
- Revenue
- HOWL $1,143,000.00
- VIGL N/A
- Revenue This Year
- HOWL N/A
- VIGL N/A
- Revenue Next Year
- HOWL N/A
- VIGL N/A
- P/E Ratio
- HOWL N/A
- VIGL N/A
- Revenue Growth
- HOWL N/A
- VIGL N/A
- 52 Week Low
- HOWL $0.60
- VIGL $1.31
- 52 Week High
- HOWL $4.18
- VIGL $7.96
- Technical
- Relative Strength Index (RSI)
- HOWL 46.17
- VIGL 88.44
- Support Level
- HOWL $1.18
- VIGL $7.86
- Resistance Level
- HOWL $1.30
- VIGL $7.90
- Average True Range (ATR)
- HOWL 0.12
- VIGL 0.03
- MACD
- HOWL -0.03
- VIGL -0.20
- Stochastic Oscillator
- HOWL 6.33
- VIGL 91.67
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.